Jefferies Maintains Buy Rating on Taysha Gene Therapies

Summary

Jefferies has maintained its ‘buy’ rating for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) with a target price of $8.00. The company is considered one of the 13 best long-term low-priced stocks, reflecting analyst confidence in its potential.MSN

Impact Analysis

This is a company-level event as it directly pertains to Taysha Gene Therapies. Jefferies’ reaffirmation of the ‘buy’ rating and the target price suggests confidence in the company’s future prospects, potentially leading to positive investor sentiment and stock price appreciation. Other analysts like Needham and a Canadian investment banking group have also maintained positive outlooks, with target prices ranging from $8.00 to $11.00, indicating a consensus on the company’s potential growth.+ 3 This positive sentiment might encourage investors to consider TSHA as an investment opportunity, particularly as analysts view it as a promising low-price stock with long-term potential.